The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Flare Therapeutics; Takeda (I)
Stock and Other Ownership Interests - Takeda (I)
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
 
Gopa Iyer
No Relationships to Disclose
 
Xin Gao
Consulting or Advisory Role - Flare Therapeutics; Myovant Sciences; PATHAI; PureTech; Silverback Therapeutics
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Drew W. Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Flare Therapeutics (Inst); GlaxoSmithKline (Inst); Kronos (Inst); Merck (Inst); Molecular Templates (Inst); PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); PCCTC (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Research to Practice
 
Benjamin Garmezy
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Exelixis (Inst); Genentech (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kinnate Biopharma (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen (Inst); AVEO (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Sanofi (Inst)
 
Ildefonso I Rodriguez Rivera
Employment - Next Oncology; Texas Oncology
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Syneos Health
 
Jennifer Tepper
Employment - Biogen (I); Flare Therapeutics
Stock and Other Ownership Interests - Alcon (I); Amgen (I); biogen (I); BioNTech SE; Danaher (I); GE Healthcare (I); Medtronic (I); Merck (I); Merck (I); Novartis (I); Pfizer (I); Procter & Gamble (I); Roche (I); Sanofi (I); Sonic Healthcare (I); The Cigna Group (I); Viatris (I)
Travel, Accommodations, Expenses - Flare Therapeutics
Other Relationship - Flare Therapeutics
 
Melissa Ann Moles
Employment - Flare Therapeutics
Stock and Other Ownership Interests - Flare Therapeutics
 
Evisa Gjini
Employment - Takeda (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; Takeda (I)
 
Michaela Bowden
Employment - Flare Therapeutics
Leadership - Flare Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Flare Therapeutics
 
Michael L. Meyers
Employment - Eilean Therapeutics; Flare Therapeutics; Syndax
Leadership - Eilean Therapeutics; Flare Therapeutics; Nuvalent, Inc.; Syndax
Stock and Other Ownership Interests - Flare Therapeutics; Johnson & Johnson; Nuvalent, Inc.; Syndax
Consulting or Advisory Role - Eilean Therapeutics; Flare Therapeutics; Nuvalent, Inc.; Syndax
Patents, Royalties, Other Intellectual Property - Nuvalent, Inc.; Syndax
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792